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ABSTRACT 
Biomarker discovery and development for clinical research, diagnostics and therapy 
monitoring in clinical trials have advanced rapidly in key areas of medicine, notably 
oncology and cardiovascular diseases, allowing for rapid early detection and supporting the 
evolution of biomarker-guided precision medicine-based targeted therapies.  
In Alzheimer’s disease (AD), breakthroughs in biomarker identification and validation 
include the cerebrospinal fluid (CSF) and positron emission tomography (PET) markers of 
amyloid β (Aβ) and tau proteins, which are highly accurate in detecting the presence of 
pathophysiological and neuropathological changes of AD. However, their high cost, 
insufficient accessibility, or invasiveness may limit their use as viable first-line tools for 
detecting patterns of pathophysiology. Therefore, a multi-stage, tiered approach is needed, 
prioritizing development of an initial screen to exclude from these tests the high numbers of 
people with cognitive deficits who do not demonstrate evidence of underlying AD 
pathophysiology.  
This perspective summarizes the efforts of a working group that aimed to survey the current 
landscape of blood-based AD biomarkers, and outlines operational steps for an effective 
academic-industry co-development and path forward from identification and assay 
development to validation for clinical use. 
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Introduction 
Alzheimer’s disease 
Alzheimer’s disease (AD) is a clinically and pathophysiologically heterogeneous complex 
neurodegenerative disease (ND). AD is the most common cause of age-related ND, impacting 
millions of individuals worldwide; currently, one out of nine people over the age of 65 are 
living with AD1 and the prevalence of AD is expected to grow exponentially over the next 
several decades1.  
The pathogenesis of AD involves interacting pathophysiological cascades, including core 
events, i.e. accumulation of the 42-amino acid-long amyloid beta peptide (Aβ1–42) into 
amyloid plaques in the brain parenchyma and the formation of intraneuronal neurofibrillary 
tangles composed of hyperphosphorylated tau protein2. Emerging evidence stresses the 
existence of additional molecular pathophysiological pathways, such as axonal 
disintegration3, synaptic dysfunction and degeneration4, innate immune response and 
neuroinflammation5,6, vascular and cell membrane dysregulation7, and brain metabolic 
dysfunction8 – across the different stages of AD. Moreover, other proteinopathies and 
pathologies frequently co-exist in the ageing brain. These include TDP-43 or α-synuclein 
proteinopathies, non-AD tauopathies, vascular pathology, and hippocampal sclerosis9-12. For 
these reasons, establishing a definitive diagnosis and developing effective treatments of AD 
is complicated.  
At present, the aetiology and pathogenesis of AD is the subject of ongoing research and 
debate. The amyloid cascade hypothesis proposes that the brain accumulation of aggregated 
forms of Aβ is the trigger and/or driver of the disease process13. However, recent studies 
raised questions about this hypothesis as the exclusive cause and/or intervening link between 
the pathophysiology of AD and its clinical phenotype. The notion that biochemical and 
cellular mechanisms generate complex cognitive alterations has renewed AD research, 
leading to replace the first descriptive studies with a molecular, mechanistic view. The 
exponential increase in knowledge on interacting pathogenic mechanisms in individuals 
suffering from AD holds promise for the development of future biomarker-guided targeted 
therapies and prevention strategies14-17.  
 
The potential impact of biomarkers on primary care and neurology for the 
detection and diagnosis of AD 
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Given the complex clinical phenomenology, clinical, neurological, and neuropsychological 
examinations are still an integral component of accurate late-stage detection of clinically 
symptomatic AD and other ND. However, waiting times for appointments with specialists in 
the U.S., U.K. and Ireland (and other countries) can be very long resulting in substantial and 
often critical delays for patients and providers18. Memory clinics or general neurology clinics 
in many countries receive a broad range of referrals covering many conditions and diseases, 
therefore the improved streamlining of referrals to specialty clinics can have a significant 
impact on health care utilization and costs18. As one example, recent U.S.-based legislation 
requires that elderly people aged 65 and older receive annual cognitive examinations as part 
of the Annual Wellness Visit (CMS.gov)19; however, older adults continue to be inadequately 
assessed for cognitive decline during primary care visits20. Given that the average duration of 
primary care visits for geriatric patients is 21 minutes21, this is perhaps not surprising. 
Additionally, cognitive examinations are regularly administered, scored, and interpreted 
incorrectly in primary care due to lack of training and expertise22,23 and there are significant 
differences between primary care and specialty care approaches to diagnosis, treatment, and 
social support24. Therefore, a process that aids primary care practitioners in deciding which 
patients should receive a referral to a memory clinic would be of substantial advantage to 
both specialists and general practitioners. Such a system would reduce the overall clinic and 
medical system burden by decreasing the numbers of unnecessary referrals and diagnostic 
procedures25,26. Biomarker-based diagnostics can greatly aid a multi-stage selection of 
patients into appropriate centres.  
To date, the literature has focused on diagnostic biomarkers27,28 for specialty clinic settings 
with little attention to screening instruments required for broad-based implementation in 
primary care settings. Additionally, diagnostic paradigms continue to rely substantially on 
clinical symptoms, with only relatively recent research guidelines taking biomarkers of AD 
pathophysiology into account29,30. Up to the mid-2000s, diagnosis of AD had a 
“clinicopathological” basis, with no definitive positive diagnosis possible until post-mortem 
confirmation of the presence of Aβ plaques and neurofibrillary tangles, and clinical diagnosis 
being assigned after a patient had reached the late-stage syndromal dementia threshold, by 
exclusion of other aetiologies of dementia29. This concept of late-stage diagnosis of exclusion 
focusing on clinical phenotype showed profound limitations, given that clinical symptoms are 
by nature heterogeneous (including an increasing number of atypical clinical phenotypes) and 
vary regarding onset, progression, and sequence of events. They have considerable overlap 
with other central nervous system (CNS) proteinopathies causing dementia as well as with 
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dementia due to cerebrovascular disease31. More recently, with the advent of reliable 
radiotracers with affinity for cerebral amyloid deposits32, and the availability of clinically 
well-validated assays for cerebrospinal fluid (CSF) detection of Aβ peptides and tau 
proteins3, there has been progress towards a “clinicobiological” diagnostic approach in which 
pathophysiological and topographic biomarkers are integrated into the diagnostic paradigm29 
as adjuncts to core clinical criteria30. These biomarkers are clinically available in specialty 
clinic settings for some countries, providing the means for dementia specialty clinicians to 
confirm diagnosis with much higher certainty through the presence of characteristic features 
of AD pathophysiology, thereby allowing for a more conclusive aetiological diagnosis14,33,34. 
Nevertheless, use of these technologies is not yet the standard and they are restricted to 
specialty clinic settings. On the other hand, biomarkers are now being incorporated into the 
comprehensive clinical diagnostic process, which will result in improved overall accuracy in 
detection of pathophysiology. However, as was the case for more matured translational 
research areas of biomedicine, such as oncology and cardiovascular medicine, the field is in 
need of biomarker-based diagnostics that can accurately and reliably identify individuals at 
risk and patients as precise and early as possible in the disease process35-39, preferentially in 
primary care settings. The availability of these biomarker-based diagnostics (e.g. CSF Aβ1–42 
and tau) is also expected to open the window for precision medicine and allow a shift away 
from the traditional “one-size-fits-all” approach with “magic bullet” drugs in neuroscience to 
the development of biomarker-guided targeted therapies25,40-43. 
Facilitation of the precision medicine paradigm in ND such as AD requires an array of 
converging advanced analysis methods. Through systems theory, it is possible to 
conceptualize original and innovative models to explicate all systems levels – assessed via 
systems biology and systems neurophysiology42 – and different data dimensions in space and 
time of the non-linear, dynamic, and chronically progressive nature of the clinically and 
biologically heterogeneous construct of polygenic AD35,44, historically developed after the 
clinical description of the first patients and the associated brain histopathological remarks45.  
The agnostic, hypothesis-free systems theory approach seems appropriate to explain the 
complex and heterogeneous origin and time course of the pathophysiological failure 
underlying the different forms of AD35. For multifactorial diseases, comprehensive holistic 
systems-level approaches are required; this is the case of the systems biology model aiming at 
understanding the genotype-phenotype relationships and the mechanisms at the level of the 
genome/epigenome, transcriptome, microRNome, proteome/peptidome, 
metabolome/lipidome, microbiome, and environmental factors participating in complex 
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cellular networks35,44,46. Longitudinal investigations using systems biology-based strategies 
help characterize the complex molecular pathophysiology of the subforms of AD, all 
evolving through the convergence of alterations of homeostasis and/or failures in many 
systems, networks, signalling pathways, or pathophysiological processes44. 
One of the key objectives of precision medicine is to bring new models for prevention, early 
detection, differential diagnosis, and treatment of AD and other ND, according to individual 
biological differences reflected by multimodal biomarkers33,35,37. Therefore, following the 
advanced models of oncology and cardiovascular medicine, innovative biomarker studies are 
expected to detect specific diagnostic, prognostic, and predictive biomarker signatures to 
adapt the therapy to individual patients40. As reported by the Institute of Medicine (IOM) 
Committee Recommendations for Advancing Appropriate Use of Biomarker Tests 
(companion diagnostics) for Molecularly Targeted Therapies, the ultimate goal of precision 
medicine is to enhance both clinical outcomes and the quality of patient care47. 
Precision medicine is being used in AD and in a growing number of ND as a result of: 1) the 
development of large-scale biological databases and 2) the evolution of advanced high-
throughput “omics” sciences. Novel methods developed within the “omics” disciplines have 
been successfully applied in the more advanced cancer area and are expected to transfertilize 
to AD and other ND. For instance, validated microarray expression profiling and current 
RNAseq technologies allow identifying differential expression of whole genomes in any 
specific sample at any given time point. Numerous reports exploiting these transcriptomics 
methods to recognize biomarkers in specific cancer subtypes are present48. The participation 
of microRNAs (miRNAs) in crucial cellular processes including cell death and their role in 
negative control of the expression of various oncoproteins make them interesting candidate 
biomarkers for cancer. Cancer-specific markers are detected in the blood from the earlier 
stages of tumor development. Since their concentration increases as tumor advances over 
time, they are useful dynamic indicators of tumor growth49. In proteomics, innovative 
methods of immuno-PCR, based on conjugations of specific antibodies and nucleic acids and 
exploiting ultrasensitive PCR signal amplification, can result into a 100 to 10,000-fold 
increase in sensitivity compared with the analogous enzyme-amplified immunoassays, hence 
considerably increasing the sensitivity of protein biomarker detection50,51. Powerful 
computational and integrative network biology tools are needed to assimilate the large 
multimodal information generated by the “omics” exploratory analyses and to 
comprehensively understand the decompensations at systems level52. An advantage in the AD 
field is that many of the pathologies are well known. Hence hypothesis-free systems theory 
8 
 
approaches may be advanced in synergy with the refinement of methods that directly reflect 
core pathologies, much like what has recently happened in the field of blood-based direct, 
Aβ-related biomarkers for amyloid pathology53-55 and blood biomarkers for axonal 
degeneration56,57. 
 
Why are blood-based biomarkers needed for AD? 
While advancements in positron emission tomography (PET) and CSF biomarker analyses 
have the potential to improve accuracy within the diagnostic process, these methods show 
limitations precluding their use as first-line diagnostic tools. These limitations would be 
countered by use of blood-based biomarkers28. If a sufficiently accurate and standardized 
blood test can be developed, it is highly likely to be more cost effective than PET scans, the 
substantially high cost of which limits accessibility, generalizability and availability58,59, 
particularly outside the U.S.A. Because of this high cost, PET testing in AD will likely only 
become reimbursed as an adjunct to other less expensive tests, as was previously the case 
with PET scans for cancer. In addition, blood testing is less invasive than CSF testing, which 
requires lumbar puncture60,61. Furthermore, blood testing is already a well-established part of 
clinical routines globally, requiring no further introduction and training for health care 
professionals (HCPs), and can be easily performed in a variety of relevant settings (including 
primary care, in community-based medicine centres or even in a patient’s home) and at 
repeated intervals62. Blood sample handling infrastructure is also well established, allowing 
for the shipping of samples during the initial development stages. Therefore, blood-based 
screening biomarkers for AD can meet the scalability needs required for primary care settings 
and even for the broad population-based screening approach that may evolve with the 
advancing innovative precision medicine framework. Finally, the use of blood-based 
biomarkers offers the potential for testing of a huge range of comprehensive exploratory and 
candidate pathophysiological biomarkers, reflecting the full spectrum of disease triggering 
and driving molecular mechanisms underlying polygenic AD, beyond the conventional 
amyloid- and tau-based tests.  
Blood-based biomarkers are an ideal choice as the first-step of the multi-stage diagnostic 
process beginning in primary care settings, and provide the means to determine which 
individuals or patients should receive referral to assessment by specialists, including 
diagnostic CSF analysis, magnetic resonance imaging (MRI) or amyloid PET diagnostics26,63, 
which is analogous to the existing process for many other conditions. In addition to meeting 
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the significant clinical need, the availability of these tools would provide a viable path 
towards regulatory64 and reimbursement approval, using the cancer paradigm as a model. 
 
Physiological challenges of developing blood-based biomarkers for AD 
Identifying potential blood-based biomarkers for CNS diseases offers several challenges 
(Figure 1). First of all, the vast complexity of blood, which contains both cells and 
extracellular fluid, needs to be considered. Blood includes a range of different molecules 
(proteins, peptides, nucleic acids, lipids, metabolites) that can be detected in plasma, 
exosomes, and cellular compartments. The latter includes erythrocytes, leucocytes, and 
platelets, isolated into distinct cell subsets via flow cytometry or via buffy coat after density 
gradient centrifugation. Given the presence of different unique cellular compartments, each 
one is a potential source of biomarkers and may introduce variability to analyses62,65. The 
diversity of blood candidate biomarkers is relevant and includes: 1) protein 
concentrations/activity/isoforms and post-translational modifications; 2) metabolic products, 
such as amino acids, carbohydrates, lipids, organic acids; 3) nucleic acids. In the latter, single 
nucleotide polymorphisms (SNPs) – DNA sequence variations occurring when a single 
nucleotide in the genome differs between members of a species – can act as biological 
markers, helping localize genes associated with the disease66. When SNPs occur within a 
gene or in a regulatory region adjacent to a gene, they may affect the gene’s function, thus 
playing a key role in disease development. The growing application of high-throughput next-
generation DNA sequencing technologies is playing a substantial role in screening whole 
genomes and, consequently, in identifying novel genetic variants affecting the risk of AD67,68. 
The 1000 Genomes Project69,70, supported by the U.S. National Human Genome Research 
Institute consortium, made significant progresses toward this aim.  
Secondly, the CNS is an effectively contained environment, and potential biomarkers may be 
present at very low concentrations in blood once they have crossed the blood–brain barrier (if 
they cross it at all as intact molecules)59,71. Indeed, there is minimal evidence of the 
peripheral effects of AD72, although there is some evidence that the blood–brain barrier may 
be increasingly compromised in normal aging and with increased AD progression73,74. Also, 
physiological mechanisms occurring peripherally may hamper the clinical utility of blood-
based AD biomarkers, e.g. acute-phase or inflammatory proteins and small molecules, and 
metabolites present also in peripheral organs59. In particular, possible confounders include: 
significant biomarker dilution, considering the modest volume of the CSF and the extensive 
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volume of the blood and extracellular fluid75; degradation in the liver or directly in the blood 
by proteases; matrix effects caused by adherence to plasma proteins or even blood cells; and 
excretion from the kidneys. These factors may substantially lower the concentrations of the 
biomarker, as well as decrease the time window for testing. A further major issue is the 
frequent existence of overlapping ND and co-morbidities in patients with AD, including 
cardiovascular, respiratory, hepatic, renal, and rheumatic disease, all of which may affect 
protein profiles in plasma59. On the other hand, since AD is a complex polygenic disease, 
amyloid and/or tau accumulation never occur in isolation of other relevant molecular/cellular 
pathophysiological mechanisms and brain systems failures in disease models. Elucidating this 
true complexity and heterogeneity, including through blood-based biomarker analyses, may 
substantially aid in a more comprehensive understanding of the disease for the generation of 
the precision medicine paradigm25,40,44. 
 
Gathering consensus on blood-based biomarker development in AD 
Given the strong rationale yet current challenges for the development of a blood-based 
biomarker for AD, an international, interdisciplinary expert working group was convened in 
March 2016 to discuss the ideal development process. The meeting was supported by Roche 
Diagnostics International. The working group was selected based on profiling of global 
experts and working groups that was done within the extensive biomarker literature search. 
Experts were selected based on their publications and involvement in research in the field of 
neurodegenerative biomarkers in CSF and in blood. The nature of support of Roche 
Diagnostics International was the assistance of organizing of scientific meetings, video, and 
teleconferences based on the scientific chair guidance and the support of the scientific writing 
agency. The meeting room as well as refreshments according to the guidance of the 
compliance guidelines were provided. 
 
Process of the working group 
Prior to the working group meeting, an in-depth comprehensive review of the literature was 
conducted (including “grey literature” – patents, press releases, and proprietary databases) to 
identify candidate biomarkers (see “Current landscape” below for further details). A 
structured and detailed pre-work survey of the meeting expert attendees provided additional 
material for analysis of the current blood-based biomarker landscape in AD and the most 
pressing challenges for the successful development of further markers. The aim of the survey 
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was to identify and rank candidate blood-based biomarkers, which were selected from the 
landscape analysis, in order of priority for further development. 
The working group itself provided a forum for definition of an ideal target product profile for 
a blood-based biomarker in AD. A critical appraisal of the selected biomarkers was then 
performed to determine if they met this ideal profile, and to assess the general quality of 
research findings and their suitability for further development. Further considerations were 
the optimal validation process for a biomarker, the best route to determine the efficacy of a 
biomarker (predictive values versus accuracy) and the ideal cohorts in which biomarkers 
could be evaluated. In-depth discussions were also held on several candidate biomarkers, 
with the aim of defining key questions critical for evaluating any potential current or future 
candidate. 
 
Current landscape 
A landscape analysis was conducted to review all blood-based biomarkers in development for 
AD globally, and then assess these biomarkers on the basis of pre-defined selection criteria in 
order to prioritize those with the greatest likelihood of successful implementation. The data 
were sourced from publications (MEDLINE® database; 2011–2015), patents (worldwide 
patents, including PCT, USA and China; 2008–2015); press releases and conference abstracts 
from eight major neuroscience or AD conferences; and ChinaBio® proprietary databases.  
After screening more than 28,000 reports, 1,404 studies of blood-based biomarkers for AD 
were identified, 1,039 of which were from publications and conference abstracts. The 1,039 
studies were categorized according to biomarker type; 18% of the studies were on the 
conventional AD biomarkers, Aβ and tau (or their associated peptides/proteins or variants), 
19% were on genetic markers, 29% were on biomarker panels, and 34% were on markers 
related to emerging mechanisms such as inflammation, immune response, oxidative stress, 
DNA damage, mitochondrial dysfunction, and neuronal or microvascular injury. The 
identified biomarkers were then screened regarding intended use, asset type, technology 
platform, test type and analyte, and whether they included human/clinical data. A final 
screening was performed to focus only on high-quality candidates, according to novelty, 
cohort quality, presence and quality of validation study, diagnostic performance, and 
perceived quality of research. The final list contained 196 candidate biomarkers, with 
biomarker panels and emerging targets being the most common categories (Figure 2A). 
Immunoassays and molecular assays were the most popular technology platforms utilized for 
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high-quality AD blood-based biomarkers, accounting for more than 70% of studies (Figure 
2B). A potential limitation of the search was the relatively narrow date range, which may 
have resulted in the exclusion of some potentially useful biomarkers that were published 
outside of this date range. The most promising biomarker candidates and the key studies, 
including those published since the original analysis, are summarized below. 
Among the conventional AD biomarkers, the ratio of Aβ1–42/Aβ1–40 has shown potential as a 
screening/diagnostic marker in several studies. Most early studies on plasma Aβ1–42, Aβ1–40, 
and Aβ1–42/Aβ1–40 using enzyme-linked immunosorbent assay (ELISA) methods, found no or 
minor differences between AD and control groups76-78. More recently, a large cohort study 
using a novel ultrasensitive immunoassay technique (single molecule array (Simoa)), showed 
weak but significant correlations between plasma and CSF levels of Aβ1–42, Aβ1–40, and Aβ1–
42/Aβ1–4055. In addition, plasma levels of Aβ1–42, Aβ1–40, and Aβ1–42/Aβ1–40 were lower in AD 
patients compared with cognitively healthy, mild cognitive impairment (MCI) and subjective 
cognitive decline (SCD) subjects55. An alternative technique for measuring Aβ peptides in 
plasma involves immunoprecipitation and mass spectrometry54,79. A pilot study found a trend 
for a reduction in both plasma Aβ1–42 and Aβ1–42/Aβ1–40 in AD compared with controls79. A 
separate study, using a modified method involving proteolytic digestion of Aβ peptides 
before mass spectrometry, found that plasma levels of Aβ1–42 and Aβ1–42/Aβ1–40 were reduced 
in amyloid PET-positive subjects54. Furthermore, plasma Aβ1–42/Aβ1–40 had a good diagnostic 
accuracy, as indicated by a receiver operating characteristic (ROC) area under the curve 
(AUC) value of 0.8865. A recent study further supports the use of immunoprecipitation–mass 
spectrometry methods to measure plasma Aβ peptides53. Nakamura and colleagues reported 
high performance of the ratios of plasma Aβ1–40/Aβ1–42 and amyloid precursor protein 
(APP)669–711/Aβ1–42, and their composite, for the prediction of amyloid PET burden53.  
Results in the field have been mixed as Lewczuk and colleagues did not demonstrate plasma 
Aβ1–40/Aβ1–42 to be a useful diagnostic in a multi-center study80. Prior work also suggests that 
plasma amyloid markers may be impacted by cardiovascular and cerebrovascular factors81,82 
and may impact the diagnostic and predictive of these markers83. Therefore, while promising, 
additional work is needed to determine if plasma Aβ has utility as a screening tool for brain 
amyloidosis and AD, including large clinical and prospective cohorts as well as direct 
comparisons of different pre-analytic and analytic methodologies since immunoprecipitation–
mass spectrometry could be difficult to generalize for clinical use84.  
Plasma levels of tau protein have also been successfully quantified using novel, highly 
sensitive immunoassay techniques, and different technologies have shown plasma tau to be 
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increased in AD compared with controls85,86. Plasma tau levels showed a strong association 
with AD in a meta-analysis (average ratio of levels in AD versus controls: 1.95, 95% 
confidence interval 1.12–3.38, p=0.02)3. A study based on the large Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) and Biomarkers For Identifying Neurodegenerative Disorders 
Early and Reliably (BioFINDER) cohorts confirmed an increase in plasma tau in AD dementia, 
but with a substantial overlap in levels with cogitively unimpaired elderly subjects87. 
Interestingly, longitudinal evaluations showed correlations between high baseline levels of 
plasma tau levels and future cognitive decline, increased atrophy rates (measured by MRI) 
and hypometabolism (measured by 18F-fluorodeoxyglucose-PET (18F-FDG-PET))87. Thus, 
current data suggest a minor increase in plasma tau in AD, although with too large overlap 
with controls to be diagnostically useful. In a recent study, elevated plasma tau levels were 
associated with cognitive decline, independent of elevated brain Aβ88, suggesting potential 
use as a non-disease specific screening tool. 
Among the emerging targets category is the axonal protein, neurofilament light (NF-L), 
which can be quantified using the ultrasensitive Simoa technique89. Serum NF-L levels are 
highly correlated with CSF levels, suggesting that blood measurements reflect brain 
pathophysiology90. A recent study on the ADNI cohort found a marked increase in plasma 
NF-L in AD cases with a ROC AUC value of 0.8757, which is comparable to the plasma Aβ1–
42/Aβ1–40 ratio results reviewed above. Plasma NF-L was highest in MCI cases with positive 
amyloid PET scans, and predicted faster cognitive deterioration, higher rate of both future 
brain atrophy (measured by MRI) and hypometabolism (measured by 18F-FDG-PET)57. 
Interestingly, a study on familial AD (FAD) showed that blood NF-L was increased not only 
in symptomatic FAD cases, but also in pre-symptomatic mutation carriers with levels 
correlating with expected estimated year of symptom onset as well as cognitive and MRI 
measures of disease stage56. These findings suggest that plasma NF-L detects 
neurodegeneration in the preclinical phase of AD. However, high plasma (or CSF) NF-L is 
not specific for AD, but found in several neurodegenerative disorders such as frontotemporal 
dementia, progressive supranuclear palsy and corticobasal syndrome91-93. Thus, plasma NF-L 
might have an application as a screening test for neurodegeneration in the initial primary care 
evaluation of patients with cognitive disturbances. 
Also in the emerging targets category is β-site amyloid precursor protein cleaving enzyme 1 
(BACE1), the β-secretase responsible for the first cleavage step required for the generation of 
Aβ peptides from APP94. Studies using ELISA-based methods have shown increased BACE1 
activity in the plasma of AD patients compared with controls95,96. A recent study found that 
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plasma BACE1 activity was increased in both MCI subjects and AD patients compared with 
healthy controls, and significantly higher in MCI subjects who progressed to AD (over 3 
years’ follow-up) than in cognitively stable MCI subjects who did not progress96. These 
results suggest that plasma BACE1 activity has potential as a biomarker to predict 
progression from MCI to AD dementia, which could be valuable in the primary care and 
clinical trials settings; however, further studies are needed to validate these findings. 
These four candidate blood-based biomarkers (Aβ1–42/Aβ1–40, tau, NF-L, and BACE1) and 
their roles in AD pathogenesis are depicted in Figure 3. 
Blood-based biomarker panels are another area of interest for AD as a combination of 
markers might show better separation between groups than single biomarkers. In recent years, 
several protein panels have shown diagnostic or prognostic potential63,97-99, including a 21-
protein panel for AD screening, which has demonstrated a positive predictive value (PPV) of 
0.85 and a negative predictive value (NPV) of 0.94 in a preliminary validation63. Non-protein 
analytes such as amino acid100, miRNA101,102, and lipid panels103 have also shown promise 
but independent, large-scale validation studies are needed.  
 
The road to the clinic 
Historical difficulties with development 
Assay reliability, and robust replication and validation of initial results are key issues for 
blood-based biomarker development26,71,104,105. Historically, an important limitation has also 
been the analytical sensitivity of available technologies; standard immunochemical methods 
have often not been sensitive enough to allow for the reliable quantification of CNS-derived 
molecules in the blood, a situation that has changed with the advent of ultrasensitive 
assays106. There is considerable variability between studies owing to inconsistencies in 
clinical cohorts (e.g. diagnostic evaluations, stage of disease), sample availability, difficulties 
in standardizing the samples themselves, and pre-analytical and analytical differences. 
Similar to CSF assays, consistent use of automated assays between studies may ameliorate 
analytical differences. However, the lack of standardization of pre-analytical protocols is also 
a major issue. For example, it is known that the majority of errors in proteomic analysis arise 
in the pre-analytical phase65,107. Pre-analytical variables can be divided into several main 
categories (Table 1)71,107. Initial steps towards standardization have already been made107, 
with the formation of a professional interest area focused on Biofluid Based Biomarkers 
(BBB-PIA) (in association with the Alzheimer’s Association’s International Society to 
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Advance Alzheimer's Research and Treatment [ISTAART]). This group will drive towards 
consensus on harmonization of pre-analytical and analytical protocols, and will lead the 
development of a repository of clinical reference samples to enable assay harmonization and 
clinical performance assessment. However, further action is needed and communication of 
these issues to wider audiences is also warranted. 
The experimental design of a biomarker evaluation study (including obtaining relevant 
cohorts with appropriate sample availability) will be important, as this has proved difficult in 
previous studies. Whilst many cohorts exist and potentially have samples suitable for use to 
develop a blood-based biomarker, these cohorts may not match the patient profile 
encountered in the target setting. Finally, any candidate biomarker will need to offer excellent 
scalability to allow for large-scale use.  
 
Ideal characteristics of a blood-based biomarker 
The first steps in development of a blood-based biomarker for AD diagnosis should be to: a) 
finalize the specific context of use (COU) for regulatory purposes; and b) determine the target 
product profile, which allows for targeted development of the biomarker to match specific 
requirements for the intended COU. This prospective approach may enhance success 
compared with current approaches based on a discovery model, where biomarkers are first 
identified in case-control studies before being retrospectively adapted to an intended COU. In 
cases where a COU is prospectively defined, the original case-control study may not be fit-
for-purpose to adequately test the COU. During the working group meeting, the consensus 
was that the COU for a blood-based biomarker in AD should be as a tool to assess patients 
reporting cognitive deficits in the primary care setting, allowing for identification of the 
subset of patients demonstrating biological signs consistent with AD who require further 
specialist diagnostic testing. Ideally, the biomarker could also be used to rule out other ND 
with symptoms similar and/or overlapping to those of AD. Validation against current clinical 
and biomarker-based diagnostic paradigms would also be required (ideally the IWG-2 
diagnostic criteria29: evidence of cognitive impairment in conjunction with amyloid PET or 
the CSF “AD signature” [reduced Aβ and elevated tau CSF concentrations]). Alternatively, it 
may be possible to employ the recently proposed biomarker-guided A/T/N descriptive 
classification system108 in the validation stage. 
The predictive accuracy requirements of a screening tool (PPV and NPV) are dependent on 
COU, in addition to the to the follow-up diagnostic resources, treatments and associated 
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costs. A primary care-based screening tool would not be intended as a “diagnostic”, but 
would serve as a gatekeeper to the confirmatory diagnostic procedures utilized by specialty 
physicians. As is the case with all primary care screening tools, the primary concern is with 
high NPV. This is due to the base rates of the conditions in the general population (which are 
typically very low) and, therefore, the screening tool serves to preclude the vast majority of 
patients who are not in need of more invasive and expensive diagnostic procedures. For 
example, in mammography screening for breast cancer and in depression screening in 
primary care, PPVs are <30%63, but are counteracted by excellent NPVs (>90%). In primary 
care settings, it is commonplace to see tools with PPVs <40% (or even <20%) but NPVs 
>90% (or even >95%)63. The overall diagnostic accuracy of the primary care screening tool 
must be taken into account alongside the full diagnostic procedures in specialty clinics where 
available that include CSF and/or PET biomarkers (which have excellent PPV) for 
confirmatory diagnostic purposes. Once disease-modifying therapeutics become available 
(for prevention or treatment of symptomatic patients109), these primary care screening tools 
become required as there will be many more patients seeking services. Therefore, the primary 
care screen will be needed to cost-contain while simultaneously broadly opening up access to 
specialty diagnostics. The consensus in the working group was that a candidate biomarker for 
primary care screening should ideally have a PPV of >50%, with an aim for this to be as high 
as possible. However, given the ethical implications of false negatives, it would be more 
important to achieve a NPV of ≥90%, with 95–98% being an ideal target63. On the other 
hand, a performance with a high PPV and an acceptable NPV may be desirable in a 
pharmaceutical setting that focuses on identifying as many amyloid-positive patients as 
possible for either inclusion in to clinical trials or a possible future treatment. 
In terms of assay technology, the consensus indicated a strong preference for panel-based 
assays (i.e. a combination of biomarkers, either developed together or individually) over 
single biomarkers. Panels may offer wider applications beyond AD diagnosis, allowing more 
generalized testing for other ND, with each pathological condition having a unique protein 
signature. Several studies established panels of biomarkers to discriminate between 
cognitively healthy controls and AD participants and assessed large arrays of differently 
combined proteins to yield high specificity and sensitivity. Indeed, since there is a definite 
need for a holistic approach to standardize blood biomarkers for AD diagnosis, it is crucial to 
understand the link among various individual biomarkers and overcome the outdated 
approach of examining single candidate biomarkers at a time110. Given that various methods 
exist to detect biomarkers in blood28,110-112, it is crucial to standardize the technologies 
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generating complex multidimensional data and the whole workflow. General consensus on 
both protocols and ultrasensitive analytical methods are needed across multicentre studies to 
set up a standardized panel of biomarkers for AD diagnosis110,111. In this regard, recent 
technical advances have provided ultrasensitive immunoassay methods that allow detecting 
and quantifying biomarkers at concentrations that are several-fold lower than those accessible 
by existing immunoassays. This may result in the development of a new array of blood 
biomarkers covering the entire spectrum of AD molecular pathophysiological mechanisms. 
Moreover, these technologies may serve as the foundation enabling the diagnosis of AD and 
other ND earlier than ever before113. 
However, the number of biomarkers in the various types of panels so far developed increases 
the complexity of manufacture and commercial development, complicates validation and 
standardization processes, and leads to increased costs. This is a significant concern when 
considering scalability to meet global primary care needs. Panel-based assays also offer an 
additional challenge, as there are risks associated with analyzing large numbers of candidate 
molecules in small numbers of patients, which may result in data over-fitting and misleading 
results so that a panel seems to perform much better than individual biomarkers, but in fact 
does not114. This can be partly offset by use of a training set to initially reduce the 
dimensionality before validation in an independent cohort115. Therefore, while the working 
group agreed that a multi-marker panel may be needed, it was also agreed that the number of 
biomarkers should be restricted as much as possible within the NPV and PPV requirements as 
this would help in meeting the validation and regulatory hurdles.  
 
Refinement and validation 
Following identification of a prioritized candidate biomarker, the biomarker will require 
refinement and validation. Refinement will involve agreeing on a best-practice protocol, 
including blood collection procedures, pre-analytical sample handling and procedures for 
harmonization between different laboratories. Validation steps are outlined below. 
Validation considerations and recommendations 
The consensus process for a pathway towards validation is shown in Figure 4. Prior to 
validation for widespread use, a biomarker should already have undergone initial clinical 
validation after the discovery analyses. Validation of target biomarkers should begin with 
assessment in a “black-and-white” panel study, in which samples would be obtained from AD 
patients diagnosed according to the International Working Group-2 (IWG-2) criteria (amyloid 
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PET or CSF AD signature), and also from cognitively normal (CN) controls. Samples would 
be divided approximately 50:50 CN:AD. This initial study would aim to establish 
concordance between the novel biomarker and gold standard methods, and would be 
performed using the original technology employed in the initial development of the 
biomarker test. Ideally, the study would be conducted by an external investigator blinded to 
the patient characteristics associated with each sample. Analysis of a black-and-white panel 
would not test the biomarker within the intended COU, but would instead attempt to 
independently validate the overall accuracy of the biomarker in a known group design. 
Notably, screening tests for AD may or may not detect MCI, and the accuracy of detection 
for MCI is likely to be lower, if even possible63. Therefore, multiple tests may be required if 
the target population is to include both early AD and MCI. 
Following the black-and-white panel, the next step would be to attempt to replicate the initial 
study results in a more representative sample set, i.e. one reflecting primary care. This second 
study would again employ the original technology from the developing laboratory while 
simultaneously beginning to transfer the technology to an existing diagnostic assay platform 
that is: a) globally available; b) capable of meeting the scalability needs for the numbers of 
assays needed when reaching primary care providers; and c) developed by an entity with 
prior experience of undergoing regulatory approval for diagnostics. Technology transfers are 
likely to be mandatory, as discovery platforms are unlikely to meet the stringent requirements 
for diagnostic assays as outlined by the Clinical Laboratory and Standards Institute 
(http://clsi.org/). Collection and assay of samples across both the original platform and the 
intended platform for use downstream in the regulatory pathway creates a built-in “bridge” 
cohort into the initial trial to test the technology within the intended COU. If strong 
concordance of results between internal and external laboratories is demonstrated following 
these studies, data acquired across the original training cohort and the new COU-specific test 
cohort (using the new technological platform) would be applicable for use in further 
refinement of the diagnostic algorithm, enabling the case for regulatory approval to be built. 
This would increase the reliability of the results. Finally, samples would be assayed on the 
intended platform for regulatory approval across multiple laboratories in order to establish 
inter-laboratory reproducibility.  
Next, the full regulatory pathway, including all additional trials that might be required, would 
be established in conjunction with regulatory authorities116-118. An additional validation study 
within an independent primary care cohort would likely be required for regulatory approval. 
For US approval, this would need to comply with U.S. Food and Drug Administration (FDA) 
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requirements for registrational studies (prospective data or robustly collected retrospective 
data). An optional further step would be validation using CSF samples collected from the 
same patients as included in the original study. Ideally, CSF samples would be collected from 
both blood-test-negative and blood-test-positive cases in the primary care setting to set the 
stage for studies examining the utility of the biomarker (or new biomarkers) in detecting 
amyloid positivity among cognitively normal elders. However, this latter use would require 
the entire process to begin anew, as this would represent an entirely different COU. 
Need for a new cohort? 
For the agreed intended use of the putative assay as a primary care screening tool, the ideal 
cohort to include in pivotal studies would align closely with the actual epidemiology of AD 
in primary care. The incidence of AD in this setting is ~10%1, a proportion which includes 
patients with either subjective or objective cognitive deficits. The ideal cohort should also 
provide access to PET and/or CSF data for all patients, and have known information for age, 
sex, APOE ε4 status and education to ensure that these are taken into account.   
Current cohorts with both CSF and blood available are largely based around dementia 
specialty clinics and, as such, do not meet the needs of the target product profile. Current 
cohorts are also limited by referral bias – they are enriched for patients with cognitive 
impairment and so do not echo the disease prevalence in primary care. An alternative to 
specifically examining primary care cohorts could be to use a yoked design, whereby the 
setting is a specialist centre with referrals from primary care where, in addition to referred 
patients, additional patients not meeting the referral criteria could be taken and included to 
make the cohort more representative. Additionally, it could be possible to work with primary 
care research networks. 
In summary, it may be necessary to recruit new cohorts for the purposes of blood-based 
biomarker assay development. Alternatively, new large-scale cohorts, such as that created as 
part of the U.S. “All of Us Research Program”, evolved from the U.S. Precision Medicine 
Initiative (PMI)119 Cohort Program (available at https://www.nih.gov/research-
training/allofus-research-program), or the UK Biobank120, could prove extremely valuable in 
the development of blood-based biomarkers, as these will represent real-world populations 
with a wide range of genetic and biomarker data available. Recently, in order to advance the 
development of the precision medicine paradigm in AD, the international Alzheimer 
Precision Medicine Initiative (APMI) and its planned pilot-cohort program (APMI-CP25,40-43) 
have been launched and thematically associated with the “All of Us Research Program”. The 
mono-centre pilot APMI cohorts, spanning from early asymptomatic preclinical populations 
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to prodromal to late-stage dementia populations, allow for the standardized recruitment of 
both cognitively intact individuals at risk for AD and patients with a full spectrum of ND to 
provide an assortment of unique heterogeneous and multidimensional data. Particularly, the 
“INveStIGation of AlzHeimer’s PredicTors in Subjective Memory Complainers” (INSIGHT-
preAD) study121 – a French mono-centric academic university-based cohort established at the 
Institute of Memory and Alzheimer’s disease (Institut de la Mémoire et de la Maladie 
d’Alzheimer, IM2A) at the Pitié-Salpêtrière University Hospital in Paris – is the key cohort of 
the APMI-CP25,40,41,43. The main goal of the INSIGHT-preAD study is to investigate the 
earliest preclinical stages of AD and its development, including influencing factors and 
markers of progression, in cognitively normal Caucasian individuals, recruited from the 
community in the wider Paris area, France, aged 70 to 85, with subjective complaint of 
memory dysfunction.  
 
Does the landscape fit the target product profile? 
Following the landscape analysis, the 196 candidate biomarkers (Figures 2A and 2B) were 
further divided into tiers according to additional criteria (outlined in Callout Box 1). Of these 
196 candidates, 19 were prioritized for further consideration by the working group (a table of 
all 19 assays is provided in the Supplementary Information); however, none were deemed to 
have met the agreed target product profile.  
 
Callout Box 1. Criteria for evaluation of identified biomarkers 
• Tier 1 – validated biomarkers 
o Markers with strong performance data that have successfully completed initial 
validation studies in subsequent reports or in a multi-centre setting with more than 120 
patients. 
• Tier 2 – high-performing biomarkers 
o Markers with good performance data that have not completed validation studies. 
Markers in this category are further divided into subgroups depending on the intended 
use and number of patients. 
 2A: Specificity and sensitivity >80%, or specificity or sensitivity >85%*, with 
an intended use of early detection, prediction or differential diagnosis and 
greater than 120 subjects 
 2B: Specificity and sensitivity >80%, or specificity or sensitivity >85%*, with 
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*Along with an adequate, non-zero score on the other parameter  
 
Most of the candidate biomarkers were limited by a lack of validation in independent cohorts 
(only five biomarker studies identified in the search have been followed up with validation 
studies) (Figure 5)97,98,122-124. This is regarded as a critical step in development and so is a 
conspicuous gap. Furthermore, where validation has been performed, it may not have been 
conducted by an independent group, and may not be based on a model published prior to the 
study105. This results in a risk of hypothesizing after results are known (HARKing), which 
can lead to selective reporting and inflated predictive accuracy125. 
Validation studies may require additional cohorts or, potentially, they could be validated 
within subgroups of the original cohort. However, appropriate cohorts for the ideal intended 
COU do not currently exist; validation between cohorts will therefore be a further hurdle in 
the development of assays. As previously discussed, the appropriate cohorts (stemming from 
patients in primary care with CSF and blood samples, as well as PET data) are not available 
and therefore the target product profile could not be met by any study.  
Additional issues present with some biomarkers are PPV and NPV values lower than those 
specified in the target product profile, as well as small sample sizes (Figure 5). Studies using 
large and well-established cohorts such as ADNI and the Australian Imaging, Biomarker and 
Lifestyle Study of Ageing (AIBL) are more likely to meet the initial requirements. As 
discussed previously, biomarker panels are thought to offer the greatest chances of success, 
although panels featuring high numbers of markers will be difficult and expensive to develop 
and validate. In addition, most available technology platforms have a low ceiling on the 
number of biomarkers that can be contained within the assay, which is usually around five 
biomarkers. There are many emerging areas of interest (e.g. exosomes) that offer promise, 
although they are too early for consideration at this time. Additionally, blood-based assays 
an intended use of early detection, prediction or differential diagnosis and less 
than 120 subjects 
 2C: Specificity and sensitivity >80%, or specificity or sensitivity >85%*, with 
an intended use of diagnosis 
 2D: Same criteria as Tier 2A–C, with markers having applications in both 
blood and CSF. 
• Tier 3 – promising candidate biomarkers 
o Innovative markers with promising performance data but have not yet produced higher 
performance results in clinical settings. 
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for well-known biomarkers of AD, such as Aβ1–42/Aβ1–40, tau, NF-L, and BACE1, may have 
potential, and should be monitored closely as more information becomes available and novel 
technologies emerge to address the hurdles currently facing use of these biomarkers.  
 
The future: blood-based biomarker diagnostics 
Blood-based biomarkers have the potential to improve detection and diagnosis for AD by 
increasing convenience, acceptability and ease of testing, as well as reducing costs. There are 
a number of key areas in which they are likely to provide most benefit. The first and most 
important of these is testing for AD in the primary care setting, which will potentially allow 
identification of patients at the earliest stages of the disease. Ideally, this would be prior to the 
development of any noticeable cognitive deficits, but this will depend on future 
developments. The advent of testing in primary care would lead to substantial changes in the 
current treatment paradigm by allowing patients to be guided towards specialist diagnostics 
(e.g. CSF or PET scans) and access to care earlier in the course of the disease. This will be 
particularly important once disease-modifying therapies (DMTs) become available, but may 
provide benefit to patients and caregivers even at the present time126.  
Once DMTs become available there will, undoubtedly, be a tremendous surge in numbers of 
patients in primary care settings seeking potential prescriptions. However, without a 
convenient primary care screen, confirmatory diagnostics will still be required (i.e. CSF, MRI 
or PET), which will act as a bottleneck in the diagnosis and treatment process, and will 
present a considerable burden in terms of costs. Availability of a multi-tiered diagnostic 
process commencing with a blood test in primary care would dramatically increase access to 
DMTs, while conveniently exclude from further diagnosis and treatment the vast majority of 
patients who would not need to undergo these expensive and invasive procedures. An 
additional potential use of blood-based AD biomarkers will be to provide a cost-effective and 
rapid test for AD pathology in order to determine the eligibility of patients for recruitment 
into clinical trials for DMTs127-129. These tests might also have applicability in the monitoring 
of disease progression and drug effects on AD pathophysiology during a trial130. As such, the 
availability of blood-based biomarker diagnostics may in fact accelerate the development of 
DMTs.  
 
Callout Box 2. Checklist for developing a blood-based biomarker  
• Define context of use and setting 
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• Define attributes of biomarker (how it enters the blood, concentrations and diurnal changes) 
• Develop detection method 
• Validate against gold standard (IWG-2 criteria) 
• Replicate in target-setting 
• Refine to reach target predictive values 
• Demonstration of technical performance 
• Validate against large, independent cohorts 
o Validated biomarkers should have a study showing a difference between AD and 
healthy controls and diagnostic utility in subjects with MCI 
 
The development of blood-based biomarkers often stalls in the early stages due to a 
disconnection between academia, where biomarkers are identified, and industry, who have 
the resources to take biomarkers further and develop them commercially (Figure 6). This 
disconnect arises from the different needs of these different sectors and from mutual mistrust 
developed following a history of poor interactions. The current initiative by the working 
group and Roche Diagnostics International represents a step in an attempt to improve that 
process, both efficiently and economically. 
 
Conclusions 
The last decade has unquestionably witnessed key progresses in the area of blood-based 
biomarkers research in AD and other ND. Human blood (plasma) holds the largest source of 
the proteome and technologies measuring even minor alterations of proteins and peptides are 
crucial tools to identify protein biomarkers in blood. For instance, mass spectrometry 
technologies can detect slight alterations of the protein concentrations and 
immunohistochemistry can recognize with high accuracy a definite protein in the living 
system. Compared with CSF markers, a validated blood-based AD biomarker would provide 
a fast, non-invasive, and cost-effective method of early detection and diagnosis for what is 
the most common age-related ND worldwide. In addition, venipuncture is a routine, safe 
procedure that does not pose any harm to the patient. As such – and differently from CSF 
sampling – the examination of blood biomarkers is accepted and more easily introduced in 
the clinical environment26. Targeting symptomatic patients in a primary care setting would 
help patients with early AD access care earlier. Development of biomarkers ideally reflecting 
all existing molecular pathophysiological mechanisms in the polygenic AD brain at distinct 
time points of progression will represent the foundation for personalized, tailored, biomarker-
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guided targeted therapies and constitute a critical step towards the dissemination of precision 
medicine in AD25,40. Furthermore, the development and implementation of a multi-stage 
diagnostic approach beginning with a blood test in primary care will increase access to 
confirmatory diagnostic modalities (such as PET imaging and/or CSF sampling) and provide 
a clear path for regulatory approval. This tiered approach is expected to increase the access to 
DMTs, once these will ultimately be available.  
Despite much research, many of the candidate blood-based biomarkers exhibit limitations 
currently preventing their use. Close cooperation and coordination is needed among academic 
institutions, industry partners, and regulatory bodies to accelerate the development of a 
blood-based biomarker assay suitable for clinical use. The assembly of novel cohorts may be 
required to allow the development of a new assay for the agreed ideal intended use of broad 
population-based screening for AD in patients in primary care.  
Applying systems biology to inspect large multidimensional blood-based “omics” data will 
enable the stratification of patient populations into well-defined subsets of patients sharing a 
common pathophysiology that, in turn, can be further explored for targeted interventions. The 
substantial use of systems biology methods to discover and validate diagnostic biomarkers of 
specific subsets of AD patients will considerably impact the progress of precision medicine in 
AD and facilitate the use of this paradigm for AD patients towards clinical reality26. 
 “Omics” sciences – providing a depiction of complex biological systems in a holistic and 
integrative manner – generate unavoidably large-scale and heterogeneous biomedical data. 
This led to open the era of “big data” in Biology and Medicine25,40,42, indicating the 
complexity and challenges presented by the combined analysis of data. These encompass an 
enormous amount of heterogeneous, disorganized, multidimensional data (from 
molecular/cellular data, to imaging, clinical, demographic, and environmental data) 
extensively produced by academic institutions, clinics, and, more recently, mobile 
devices131,132. The implementation of systems biology to attain novel insights into AD 
pathophysiology requires the assessment of big and deep multidimensional heterogeneous 
data. Performing the integrated analysis of big data depends on the accessibility to 
appropriate tools, both for data storage/management and for their modelling, according to 
disease pathophysiology. Therefore, effective and sophisticated methods will be essential to 
systematically screen for novel blood-based biomarkers associated with AD, as well as to 
gain insights into their spatiotemporal interactions with other biomarker categories. The 
integration of the results obtained with different experimental strategies is assumed to provide 
complementary information on the disease pathophysiology and provide insights into its 
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clinical interpretation. Accordingly, the Big Data Research and Development Initiative 
(available at https://obamawhitehouse.archives.gov/blog/2012/03/29/big-data-big-deal), 
announced by the previous Obama Administration, is a crucial promoter of the 
implementation of precision medicine through the integration of big and deep biomedical 
data. The ability to deal with “big data science”, accompanied by the implementation of an 
integrative disease modelling133, is an essential aspect of the previously mentioned 
international APMI and other worldwide initiatives, including the previously mentioned 
Alzheimer’s Association ISTAART BBB-PIA71 and the recently established Cholinergic 
System Working Group (CSWG)134. 
 
 
GLOSSARY 
Technical definitions  
α-Synuclein 
α-Synuclein is a neuronal protein involved in regulating the synaptic vesicles pool size, 
trafficking, membrane dynamics, and neurotransmitters release. Intracellular aggregates of α-
synuclein are typical of certain neurodegenerative diseases (α-synucleinopathies) including 
Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. α-Synuclein 
aggregates are also found in other neurodegenerative diseases, including AD. 
ADNI  
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, 
multicentre study, initiated in the U.S.A. in 2004, designed to develop and validate clinical, 
imaging, biochemical, and genetic, biomarkers for the early detection and tracking of AD. 
AIBL 
The Australian Imaging, Biomarker and Lifestyle Study of Ageing (AIBL) is an ongoing, 
longitudinal study, initiated in Australia in 2006, exploring biomarkers, cognitive 
characteristics, as well as health and lifestyle factors associated with AD. 
Amyloid precursor protein (APP) 
APP is a type I membrane protein abundantly expressed in the brain and implicated in neural 
growth and maturation. APP can be processed via the non-amyloidogenic pathway, where 
cleavage by α- and γ-secretases generate a secreted form of APP (sAPPα) and C-terminal 
fragments (CTF 83, p3 and AICD50). Alternatively, APP can be processed via the 
amyloidogenic pathway, where cleavage by β- and γ-secretases generate a secreted form of 
APP (sAPPβ), C-terminal fragments (CTF 99 and CTF 89) and Aβ peptides. 
Amyloid beta (Aβ) 
Aβ peptides are produced in variable length, including the 42-amino acid-long and the 40-
amino acid-long amyloid beta peptides (Aβ1–40 and Aβ1–42), from the proteolytic cleavage of 
the amyloid precursor protein. Aβ1–42 exhibits a substantial propensity to form aggregates, 
including extracellular amyloid plaques, which are a pathological hallmark of AD.  
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A/T/N 
The A/T/N scheme is a classification system that uses three binary biomarker categories 
reflecting AD pathophysiology. ‘A’ refers to biomarkers of amyloid beta pathology (CSF 
Aβ1–42 or amyloid PET), ‘T’ refers to biomarkers of tau pathology (CSF hyperphosphorylated 
tau or tau PET), and ‘N’ refers to biomarkers of neurodegeneration or neuronal injury (CSF 
total tau, 18F-fluorodeoxyglucose-PET (18F-FDG-PET), structural MRI).108  
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) 
BACE1 is an endoprotease responsible for the first proteolytic cleaving step in the generation 
of Aβ peptides from the amyloid precursor protein. 
BioFINDER 
The Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably 
(BioFINDER) study is an ongoing longitudinal study, initiated in Sweden in 2010, 
investigating the early diagnosis and underlying pathologies of AD and Parkinson’s disease 
based on neuroimaging, cerebrospinal fluid, blood-based, clinical and neuropsychological 
markers. 
Cerebrospinal fluid (CSF) 
CSF is the body fluid within the central canal of the spinal cord and the four ventricles of the 
brain. 
Context of use (COU) 
A COU is a statement that describes the manner and purpose of use for the biomarker in drug 
development. The supporting data and analyses submitted with the biomarker qualification 
determine the acceptability of the qualified COU. 
IWG-2 
The IWG-2 criteria are research diagnostic criteria for AD, developed by the International 
Working Group (IWG) for the diagnosis of AD.29 
Mild cognitive impairment (MCI) 
MCI causes a slight but noticeable and measurable decline in cognitive abilities, including 
memory and thinking skills. An individual with MCI is at an increased risk of developing AD 
or another form of dementia. 
Negative predictive value (NPV) 
The NPV is the probability a patient does not have the disease when the test result is negative. 
Neurofilament light (NF-L) 
NF-L chain protein is a component of neurofilaments, which are structural constituents of the 
neuronal cytoskeleton. It is highly expressed in large-calibre myelinated axons and is released 
into the brain interstitial fluid, following axonal injury. 
Plasma 
Plasma is the liquid constituent of blood obtained after removal of blood cells. 
Positive predictive value (PPV) 
The PPV is the probability a patient has the disease when the test result is positive. 
Receiver operating characteristic (ROC) 
The ROC curve is a plot of sensitivity versus 1-specificity for the different possible cut-off 
points of a diagnostic test. Accuracy of the diagnostic test is based on the area under the ROC 
curve; the closer the area under the ROC curve is to 1, the better the test. 
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Sensitivity 
Diagnostic sensitivity is the probability a test result is positive when the disease is present. 
Serum 
Serum is the clear liquid constituent of blood characterized by the absence of the coagulation 
factors and blood cells 
Specificity 
Diagnostic specificity is the probability a test result is negative when the disease is absent. 
Subjective cognitive decline (SCD) 
SCD is a self-reported decline in cognition, undetected by standard neuropsychological tests. 
Tau 
Tau is a microtubule-associated protein that modulates the stability of axonal microtubules. In 
AD and other neurodegenerative diseases (tauopathies), aggregates of abnormally 
phosphorylated (hyperphosphorylated) tau proteins result in intraneuronal neurofibrillary 
tangles. 
TDP-43 
Transactive response DNA-binding protein 43 (TDP-43) binds both DNA and RNA and helps 
regulate mechanisms of RNA processing such as splicing, trafficking, and microRNA 
production. TDP-43 cytoplasmic inclusions are associated with definite neurodegenerative 
diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, and AD.  
 
Conceptual definitions  
Big Data  
Big Data is a repository of large amounts of data sets generated by data mining tools. Big 
Data includes information obtained through systems theory- and knowledge-based 
approaches, and clinical records.  
Data science 
Data science is an interdisciplinary field about processes and systems to extract knowledge 
from data in different forms – either structured or unstructured – which is a continuation of 
some of the data analysis fields including statistics, artificial intelligence, machine learning, 
data mining, and predictive analytics. 
Homeostasis 
Homeostasis is a spontaneous tendency towards a condition of a dynamic equilibrium based 
on a continuous counterbalance between regulatory-defense mechanisms and disrupting 
stress-induced signals. Homeostasis is common to any biological system. Homeostatic 
signalling is hierarchically organized from subcellular to cellular level, across organs, and, 
finally, systems. Homeostasis is essential for protecting all core biosynthetic processes 
necessary to optimal functioning and survival. 
Integrative disease modelling 
Integrative disease modelling is a multidisciplinary approach to standardize, manage, 
integrate, and interpret multiple sources of structured and unstructured quantitative and 
qualitative data across biological scales using computational models that assist decision 
making for translation of patient-specific molecular mechanisms into tailored clinical 
applications.  
Network 
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A network is a set of recurring motifs; each motif is a pathway; each pathway, in turn, carries 
out specific dynamical functions and can be modulated, i.e. up-down regulated, either 
upstream or downstream or both. There is a large spectrum of biological cross-talks between 
pathways and networks inside a level of a given system and among systems. 
“Omics”  
“Omics” are high-throughput screening tools aimed at fully collecting, characterizing and 
quantifying pools of biological molecules (DNA sequences, transcripts, miRNAs, 
proteins/peptides, metabolites/lipids) that translate into the structure, function, and dynamics 
of an organism and/or whole organisms. 
“One-size-fits-all” approach 
The “one-size-fits-all” approach is the traditional approach used for the development of early 
detection, intervention, and prevention options, where biomarker candidates are being 
validated against the plethora of heterogeneous clinical operationalized syndromes, rather 
than against genetically (risk profile) and biologically (i.e., based on molecular mechanisms 
and cellular pathways) determined entities. 
Precision medicine 
Precision medicine is a translational science paradigm related to both health and disease. It is 
a biomarker-guided targeted medicine on systems-levels taking into account methodological 
advancements and discoveries of the comprehensive pathophysiological profiles of complex 
polygenic, multi-factorial neurodegenerative diseases (proteinopathies of the brain). Precision 
medicine aims to optimize the effectiveness of disease prevention and therapy, by considering 
(customizing) an individual’s specific “biological make-up” (e.g. genetic, biochemical, 
phenotypic, lifestyle, and psychosocial characteristics) for targeted interventions through P4M 
(Predictive, Preventive, Personalized, and Participatory) implementation. 
Systems biology 
Systems biology is an evolving hypothesis-free, exploratory, holistic (non-reductionistic), 
global, integrative, and interdisciplinary paradigm using advances in multimodal high-
throughput technological platforms that enable the examination of networks of biological 
pathways where elevated amounts of structurally and functionally different molecules are 
simultaneously explored over time at a system level (i.e., at the level of molecules and 
subcellular compartments, cells, group of cells, tissues, organs, apparatuses, or even whole 
organisms). According to systems biology, organisms are made of systems which are entities 
consisting in hierarchically self-organized levels with increasing structural complexity 
resulting in different emerging properties. 
Systems theory  
Systems theory is a translational research theory of the precision medicine paradigm. It is an 
interdisciplinary conceptual framework allowing for the conceptualization of novel/original 
models to extract and explicate all systems levels and different spatiotemporal data types of 
complex polygenic diseases. 
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FIGURES 
  
Figure 1. Challenges in developing a blood-based biomarker of CNS disease.  
There are several considerations when finding a biomarker for a CNS disease, particularly if 
the biomarker is to be blood-based.  
Blood–brain barrier: biomarker must be able to cross the blood–brain barrier to allow 
detection (A). Diurnal differences in CSF and blood: diurnal differences in protein 
concentrations exist in both CSF and blood. Biomarker levels may not peak at the same time 
in CSF as in blood, and a biomarker assay will either require sampling at the peak 
concentration, or sufficient sensitivity to detect the biomarker throughout the day (B). 
Active/passive transport: biomarkers may originate in either CSF or blood. Those originating 
in CSF may enter the blood via active or passive transport, and understanding the exact 
nature of the derivation from CSF will be essential to develop an assay (C). Concentration 
differences: biomarker levels are not always similar in CSF and blood. For example, Aβ 
concentrations are 10-fold lower in plasma than in CSF (35 pg/ml vs. 350 pg/ml) (D).  
Abbreviations: Aβ=amyloid beta; CNS=central nervous system; CSF=cerebrospinal fluid.  
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Figure 2. Candidate blood-based biomarkers identified in the landscape analysis. 
Technology (A) and platform (B) categories for the 196 high-quality studies identified in the 
landscape analysis. 
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Figure 3. Schematic representation of promising blood-based biomarker candidates 
Four promising blood-based biomarker candidates are represented in this schematic: 
Aβ: Aβ peptides, in particular Aβ1–42, are implicated in AD pathogenesis; however, it is the 
ratio of Aβ1–42/Aβ1–40 that appears to be the most promising Aβ-related biomarker in the 
blood. 
BACE1: The first step in the generation of Aβ peptides is the cleavage of APP by the β- 
secretase, BACE1. Measurement of BACE1 activity in the blood may be useful for predicting 
progression from MCI to AD dementia. 
Tau: Phosphorylated tau protein is a major component of intraneuronal neurofibrillary 
tangles, which are often present in AD. The abnormal phosphorylation of tau is thought to be 
driven by Aβ peptides. Tau levels in the blood may be useful as a predictor of future 
cognitive decline. 
NF-L: NF-L is an axonal protein, released into the brain interstitial fluid following 
neuronal/axonal injury. NF-L levels in the blood are elevated in AD and other 
neurodegenerative diseases, therefore, blood-based NF-L could be useful as a biomarker of 
neurodegeneration. 
Abbreviations: Aβ=amyloid beta; AD=Alzheimer’s disease; APP=amyloid precursor protein; 
BACE1=β-site amyloid precursor protein cleaving enzyme 1; MCI=mild cognitive impairment; 
NF-L=neurofilament light.  
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Figure 4. Idealized validation process for blood-based biomarkers.  
Abbreviations: AD=Alzheimer’s disease; CSF=cerebrospinal fluid; MCI=mild cognitive 
impairment.  
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Figure 5.Validation status and patient numbers of the 19 prioritized biomarkers.  
Few of the current blood-based biomarker assays in development have undergone validation 
in an external cohort. Of the 26% of assays that had some degree of external validation, only 
2 (10·5%) were in large cohorts such as ADNI or AIBL (A). Studies are often underpowered, 
with small patient numbers (B).  
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 Figure 6. Potential collaboration points between academia and industry.  
Academic and industrial approaches to biomarker development are inherently different, but 
could be extremely useful if combined. Close collaboration between industry and academia 
would allow for sharing of expertise in product testing, access to cohorts and clinical data, as 
well as allow for sharing ideas and theories with regards to clinical endpoints and context. By 
merging the two approaches, a method where the context of use is the primary focus 
throughout the process can be established. This would allow for synergistic development of a 
new biomarker between academics and industrial partners, sharing a wealth of experience. 
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TABLES  
Table 1. Pre-analytical factors influencing results of blood-based biomarker 
measurements. 
 
 
 
 
Patient-related 
factors Blood collection Blood processing Sample storage 
Demographics (age, 
sex, weight, 
ethnicity) 
Needle gauge Time to storage Storage temperature 
Diet, including 
supplements 
Needle composition 
Centrifugation 
(presence and type of 
separator, 
temperature, number 
of rounds [single or 
double]) 
Storage volume 
Health status Withdrawal site 
Addition of protease 
inhibitor 
Number of freeze-
thaw cycles 
Medication 
Collection tube 
characteristics 
Use of denaturation 
step or protein 
extraction 
Duration 
Drug/alcohol use Anticoagulant use 
Use of plasma or 
serum 
 
Medical conditions Time of collection   
Exercise    
Posture/bed rest    






